Abstract |
The NCI Canada Clinical Trials Group conducted a phase II study of menogaril given intravenously every 4 weeks in low-grade non-Hodgkin's lymphoma. Fifteen of 26 eligible patients had had no prior therapy. Partial responses were seen in 9 patients (35%). Toxicity was moderate including myelosuppression, nausea, phlebitis, alopecia, and lethargy. This drug has only modest activity in this potentially responsive group of patients.
|
Authors | J Skillings, C Cripps, E Eisenhauer, J Pater, S Verma, D Walde |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 9
Issue 1
Pg. 79-82
(Feb 1991)
ISSN: 0167-6997 [Print] United States |
PMID | 1827434
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Menogaril
- Nogalamycin
|
Topics |
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Drug Evaluation
- Humans
- Injections, Intravenous
- Lymphoma, Non-Hodgkin
(drug therapy)
- Menogaril
- Middle Aged
- Nogalamycin
(administration & dosage, analogs & derivatives, therapeutic use)
|